Tempus: Short Seller Attack Brings Golden Opportunity Cathie Wood Was Waiting For

Tempus AI (TEM) shares plunged 19% after a short-seller report from Spruce Point Capital questioned the company's credibility; however, Cathie Wood's ARK ETFs acquired 251,080 shares worth $16.5 million amidst the selloff. Despite the negative report, Tempus also flashed a bullish golden cross technical indicator, with its 50-day moving average crossing above its 200-day moving average, suggesting a strengthening long-term trend, though near-term trends remain shaky.

Analysis

Tempus AI (TEM) experienced significant share price volatility, plunging over 19% following a critical report from short-seller Spruce Point Capital that questioned the company's credibility and AI capabilities. In a notable counter-move, Cathie Wood’s ARK ETFs acquired 251,080 TEM shares, valued at over $16.5 million, signaling conviction in the precision medicine company despite the negative sentiment. This institutional buying occurred as Tempus AI's stock chart formed a 'Golden Cross,' a bullish technical indicator where the 50-day simple moving average ($52.61) crossed above the 200-day simple moving average ($52.18), with the stock trading at $55, above both averages. Further supporting a potentially positive long-term outlook, the MACD indicator stood at a bullish 1.76 and the RSI at 47.07 indicated the stock was neither overbought nor oversold. However, a near-term bearish trend persists, with the stock trading below its 8-day and 20-day simple moving averages, reflecting ongoing selling pressure. Fundamentally, Tempus AI is not yet profitable but reported a strong revenue beat in the first quarter and has supported nearly 1,500 research projects, indicating substantial operational activity in its sector. This confluence of a short-seller attack, significant institutional buying, and conflicting technical signals presents a complex picture, aligning with investment strategies that target companies with long-term potential currently facing market skepticism.

Key Decisions for Investors

• Investors should carefully weigh the allegations from the Spruce Point Capital report against ARK Invest's substantial share purchase and Tempus AI's reported first-quarter revenue beat and extensive research involvement.
• Monitor Tempus AI's price action relative to its short-term moving averages (8-day and 20-day) for signs of stabilization, while considering the longer-term bullish implication of the recently formed Golden Cross and supportive MACD and RSI readings.
• Acknowledge the heightened risk profile associated with Tempus AI, given its current lack of profitability and the sharp share price decline, making it suitable for investors with a higher risk tolerance and a focus on disruptive, long-term growth narratives in the precision medicine space.